Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack (ABC-AVC)
|Ischemic Stroke Transient Ischemic Attack|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack :Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke|
|Actual Study Start Date:||March 2007|
|Study Completion Date:||February 2017|
|Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Patients with ischemic stroke or TIA will be included in the 48 hours following the onset of symptoms, in 3 university hospitals.For each patient will be collected
- 1 blood sample for the BNP measure in pg/ml
- 1 blood sample for the Cystatin C measure in mg/l
- 2 urinary samples to measure the albumine/creatinine ratio, at inclusion and 5 days after the inclusion, and to study the variation of albuminuria in micrograms/min.
The clinical follow-up will be organized during 3 years. The following events will be notified: poor outcome (defined with the Barthel and Rankin scores), recurrence of cardiovascular or cerebrovascular events, vascular death.
After adjustment on the main clinical prognosis factors, we want to determine wich one of these markers has the best prognosis significance and allows to identify in the acute phase the "high-risk" patients, in order to intensify individual treatment and secondary prevention.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00479518
|Service de Neurologie / Hopital LAENNEC|
|Nantes, France, 44093|
|Service de neurologie / CHU Pontchaillou|
|Rennes, France, 35033|
|Service de Neurologie / CHRU de Tours|
|Tours, France, 37044|
|Principal Investigator:||BONNAUD Isabelle, MD||Service de Neurologie / CHRU de Tours|